Benefits and Tolerance of Exercise in Patients With Generalized and Stabilized Myasthenia Gravis
NCT ID: NCT02066519
Last Updated: 2018-08-13
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
NA
45 participants
INTERVENTIONAL
2014-10-31
2018-04-06
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Exercise in Autoimmune Myasthenia Gravis and Myasthenic Syndromes
NCT05408702
Effects of Whole-body Electrical Muscle Stimulation Exercise on Adults With Myasthenia Gravis
NCT06064695
Digital Phenotyping and Lifestyle Intervention in Patients with Myasthenia Gravis
NCT05992025
Education Program in Myasthenia
NCT04714658
Open-Label Extension of Tocilizumab in Subjects With Generalized Myasthenia Gravis
NCT05716035
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
During the 3 months pre-inclusion phase, the characteristics of MG will be collected. Physical activity and performance will be assessed monthly.
MGQOL15 will be assessed at inclusion.
Patients will be randomized in either intervention arm or control arm.
The intervention arm will consist of three sessions exercise per week during three months. The daily exercise will be performed on a rowing machine that will be adapted to the patient's own physical ability.
Physical activity will be measured with the help of an actimeter.
Once a month, MG evolution and tolerance to exercise will be assessed and MG treatment dose will be collected.
Exercise will be interrupted in case of MG exacerbation.
Quality of life and psychological status will be assessed at 3, 6 and 9 months.
Plasma levels of pro and anti-inflammatory cytokines will be measured at 3, 6 and 9 months in order to assess the effects of exercise on immune response.
Patients enrolled in the control arm will benefit from the same follow-up but will not have exercise.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
SINGLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Physical exercise arm
Arm with physical exercise on rowing machine between M3 and M6
Physical exercise programme using a rowing machine
3 sessions per week of individualized physical training using a rowing machine during 3 months.
Control arm
Arm with standard medical care without additional physical exercise
No interventions assigned to this group
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Physical exercise programme using a rowing machine
3 sessions per week of individualized physical training using a rowing machine during 3 months.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* positive dosage of ant-RACh or MuSK auto-antibodies;
* If absent, myasthenic symptoms decrement\> 10% in EMNG and test the positive prostigmine
2. Patient ≥ 18 and ≤ 70 years old
3. Patient having an health insurance
4. Informed written consent
Exclusion Criteria
2. Enrolment in another biomedical research in the last 3 months;
3. Patients for whom physical practice is contra-indicated because of :
* Unstable coronary Syndrome or myocardial infarction within the past 3 months
* Heart failure with systolic ejection fraction \< 50 %
* Respiratory failure defined by a vital capacity (CV) \< 70 %
* Stroke
* Other neuromuscular pathology
* Disabling Rheumatologic disease (\> 80 % disability according to the Barthel scale)
* Chronic Pain or disabling orthopaedic conditions
* Hospitalization in the last 3 months for a serious medical or surgical condition
* Anemia (hematocrit \< 30%)
4. MGFA grade I, grade IV or V
5. Severe cognitive impairment
6. MGQOL-15 below 15/60
18 Years
70 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Assistance Publique - Hôpitaux de Paris
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Tarek SHARSHAR, MD, PhD
Role: PRINCIPAL_INVESTIGATOR
ICU and medical surgery Service, Raymond Poincaré Hospital, 92380 Garches, France
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
ICU and medical surgery department, Raymond Poincaré Hospital
Garches, Hauts-de-Seine, France
Countries
Review the countries where the study has at least one active or historical site.
References
Explore related publications, articles, or registry entries linked to this study.
Birnbaum S, Porcher R, Portero P, Clair B, Demeret S, Eymard B, Gargiulo M, Louet E, Berrih-Aknin S, Le Panse R, Aegerter P, Hogrel JY, Sharshar T; MGEX Study Group. Home-based exercise in autoimmune myasthenia gravis: A randomized controlled trial. Neuromuscul Disord. 2021 Aug;31(8):726-735. doi: 10.1016/j.nmd.2021.05.002. Epub 2021 May 27.
Birnbaum S, Hogrel JY, Porcher R, Portero P, Clair B, Eymard B, Demeret S, Bassez G, Gargiulo M, Louet E, Berrih-Aknin S, Jobic A, Aegerter P, Thoumie P, Sharshar T; MGEX Study Group. The benefits and tolerance of exercise in myasthenia gravis (MGEX): study protocol for a randomised controlled trial. Trials. 2018 Jan 18;19(1):49. doi: 10.1186/s13063-017-2433-2.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
P111106
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.